Results 51 to 60 of about 1,004,261 (415)

Multi-site Diagnostic Classification Of Schizophrenia Using 3D CNN On Aggregated Task-based fMRI Data [PDF]

arXiv, 2022
In spite of years of research, the mechanisms that underlie the development of schizophrenia, as well as its relapse, symptomatology, and treatment, continue to be a mystery. The absence of appropriate analytic tools to deal with the variable and complicated nature of schizophrenia may be one of the factors that contribute to the development of this ...
arxiv  

ChronoPscychosis: Temporal Segmentation and Its Impact on Schizophrenia Classification Using Motor Activity Data [PDF]

arXiv, 2023
Schizophrenia is a complicated mental illness characterized by a broad spectrum of symptoms affecting cognition, behavior, and emotion. The task of identifying reliable biomarkers to classify Schizophrenia accurately continues to be a challenge in the field of psychiatry.
arxiv  

SCHIZOPHRENIA

, 2023
This article provides detailed information about schizophrenia. In particular, the following article provides detailed information on the causes of schizophrenia, diagnosis methods, and treatment measures for this disease.
openaire   +3 more sources

Schizophrenia and the eye

Schizophrenia Research: Cognition, 2015
Although visual processing impairments are common in schizophrenia, it is not clear to what extent these originate in the eye vs. the brain. This review highlights potential contributions, from the retina and other structures of the eye, tovisual processing impairments in schizophrenia and high-risk states.
Richard B Rosen, Steven M. Silverstein
openaire   +4 more sources

Meta-learning on Spectral Images of Electroencephalogram of Schizophenics [PDF]

arXiv, 2021
Schizophrenia is a complex psychiatric disorder involving changes in thought patterns, perception, mood, and behavior. The diagnosis of schizophrenia is challenging and requires that patients show two or more positive symptoms for at least one month. Delays in identifying this debilitating disorder can impede a patient ability to receive much needed ...
arxiv  

Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? [PDF]

, 2013
In light of the number of studies conducted to examine the treatment of cognitive impairment associated with schizophrenia (CIAS), we critically reviewed recent CIAS trials.
Buchanan, Robert W, Dugar, Ashish, Keefe, Richard SE, Marder, Stephen R, Schooler, Nina R, Stewart, Michelle, Zivkov, Milana   +6 more
core  

Patterns of primary care and mortality among patients with schizophrenia or diabetes: a cluster analysis approach to the retrospective study of healthcare utilization [PDF]

, 2009
Background Patients with schizophrenia have difficulty managing their medical healthcare needs, possibly resulting in delayed treatment and poor outcomes.
AJ Selim, Alexander L Miller, American Psychiatric Association, B Starfield, BS Everitt, Chen-Pin Wang, EP Fischer, FC Blow, GL Daumit, J Kreyenbuhl, J Parks, JF McCarthy, John E Zeber, L Dixon, L Shi, LA Chwastiak, LA Copeland, Laurel A Copeland, LB Dixon, LE Kazis, Marcia Valenstein, Michael L Parchman, MJ Pugh, ML Parchman, ML Parchman, MM Desai, MS Aldenderfer, MT Lambert, MW Sohn, PL Hebert, R Rosenheck, S Brown, S Brown, S Schneeweiss, TJ Lambert, Valerie A Lawrence, Y Shen   +36 more
core   +4 more sources

Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?

Schizophrenia bulletin, 2000
There has been a surge of interest in the functional consequences of neurocognitive deficits in schizophrenia. The published literature in this area has doubled in the last few years.
Michael F. Green, R. Kern, D. Braff, J. Mintz   +3 more
semanticscholar   +1 more source

Reservoir‐Type Subcutaneous Implantable Devices Containing Porous Rate Controlling Membranes for Sustained Delivery of Risperidone

Advanced Healthcare Materials, EarlyView.
This study presents a novel implantable drug delivery systemwith a biodegradable poly(caprolactone) membrane and compressed drug core forsustained release. These implantable devices deliver risperidone in vitro for 170 days and in vivo for 49 days in rats, showing promise for chronic conditions like schizophrenia.
Linlin Li, Andi Dian Permana, Juan Domínguez‐Robles, Muh Nur Amir, Habibie Habibie, Qonita Kurnia Anjani, Li Zhao, Natalia Moreno‐Castellanos, Ryan F Donnelly, Eneko Larrañeta   +9 more
wiley   +1 more source

Effectiveness of Virtual - Compensatory Cognitive Training (V-CCT) for improving cognition in persons with schizophrenia - a multi- centre randomized controlled trial

Trials
Background Cognitive deficits are the core component in persons with schizophrenia which impacts their socio-occupational functioning. Also, cognitive deficits cause significant impairment with the person’s quality of life [3].
Sonia Sims, Suvarna Jyothi Kantipudi, Yogitha Ashok, B. Nisha, Subhashini Gopal, Elsa Joseph, S. Amritha, Lakshmi Venkatraman, Pratiksha Venkatasubramanian, Padmavati Ramachandran   +9 more
doaj   +1 more source